"Alendronate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
| Descriptor ID |
D019386
|
| MeSH Number(s) |
D02.705.429.500.100
|
| Concept/Terms |
Alendronate- Alendronate
- Aminohydroxybutane Bisphosphonate
- Bisphosphonate, Aminohydroxybutane
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate
Alendronate Sodium- Alendronate Sodium
- Sodium, Alendronate
- Alendronate Monosodium Salt, Trihydrate
|
Below are MeSH descriptors whose meaning is more general than "Alendronate".
Below are MeSH descriptors whose meaning is more specific than "Alendronate".
This graph shows the total number of publications written about "Alendronate" by people in this website by year, and whether "Alendronate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 4 | 0 | 4 |
| 2002 | 1 | 0 | 1 |
| 2019 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alendronate" by people in Profiles.
-
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. J Bone Miner Res. 2020 01; 35(1):36-52.
-
Reply. J Allergy Clin Immunol. 2019 09; 144(3):873-874.
-
Loss of bronchoprotection with ICS plus LABA treatment, ß-receptor dynamics, and the effect of alendronate. J Allergy Clin Immunol. 2019 08; 144(2):416-425.e7.
-
Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Renal Physiol. 2014 May 01; 306(9):F1081-7.
-
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 Dec 03; 137(11):875-83.
-
Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000 May; 85(5):1783-8.
-
Effect of alendronate on immature human dental root explants. J Endod. 2000 Mar; 26(3):133-7.
-
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000 Feb; 85(2):720-6.
-
Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther. 2000 Jan; 22(1):15-28.
-
Alendronate in the treatment of postmenopausal osteoporosis. Int J Clin Pract Suppl. 1999 Apr; 101:27-35.